Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma

This article was originally published here

Velocity Pharmaceutical Development, along with Dr John Nestor, had established Spitfire for the development of SP-1373, a potent GLP-1/Glucagon receptor co-agonist to treat non-alcoholic steatohepatitis (NASH). Under the

The post Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply